Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.

Li Q, Zhang Q, Wang R, Hong T

Diabetes therapy : research, treatment and education of diabetes and related disorders6 Dec 2021

PMID34870792PMCIDPMC8776932DOI10.1007/s13300-021-01182-zPepBankPUB-34870792

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In Chinese patients with uncontrolled diabetes, dulaglutide reduced HbA1c more than glargine in most subgroups, with numerical benefit in low FG/high PPG.
In plain wordsDulaglutide lowered HbA1c more than glargine in most Chinese patient subgroups, with a numerical difference in the low FG/high PPG subgroup.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction by glycemic subgroup
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
After 26 weeks, dulaglutide 1.5 mg led to statistically greater decreases in HbA1c from baseline versus glargine in most subgroups, including the high FG subgroups, and a numerically greater decrease in HbA1c was observed in the low FG/high PPG subgroup.
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
Report a problemFND-3487079203
02HumanNon-randomized trialEfficacy outcome
In Chinese patients, dulaglutide increased attainment of HbA1c ≤ 6.5% versus glargine across all glycemic subgroups.
In plain wordsMore Chinese patients reached HbA1c ≤ 6.5% with dulaglutide than with glargine in every subgroup.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c target attainment
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Across all subgroups, higher proportions of patients achieved HbA1c ≤ 6.5% with dulaglutide 1.5 mg than with glargine (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
Report a problemFND-3487079204
03HumanNon-randomized trialEfficacy outcome
In Chinese patients, dulaglutide provided better body weight control than glargine across all glycemic subgroups.
In plain wordsDulaglutide controlled body weight better than glargine in every Chinese patient subgroup.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBody weight control
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide 1.5 mg showed better control of body weight than glargine in all subgroups (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
Report a problemFND-3487079205
04HumanNon-randomized trialEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide reduced fasting glucose across HbA1c categories.
In plain wordsIn patients with uncontrolled diabetes, fasting glucose decreased during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting glucose reduction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 or 0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide reduced HbA1c through reductions in both FG and PPG across HbA1c categories in T2D patients with uncontrolled hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
Report a problemFND-3487079206
05HumanNon-randomized trialEfficacy outcome
In patients with uncontrolled type 2 diabetes, dulaglutide reduced postprandial glucose across HbA1c categories.
In plain wordsIn patients with uncontrolled diabetes, postprandial glucose decreased during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial glucose reduction
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 or 0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
Dulaglutide reduced HbA1c through reductions in both FG and PPG across HbA1c categories in T2D patients with uncontrolled hyperglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
Report a problemFND-3487079207

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among dulaglutide-treated Chinese patients, higher HbA1c was associated with greater fasting glucose contributions at baseline and week 26.
In plain wordsIn Chinese patients receiving dulaglutide, higher HbA1c was linked to greater fasting glucose contributions at baseline and during treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseFasting glucose contribution by HbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Among patients receiving dulaglutide, higher HbA1c was associated with higher relative contributions of FG and lower relative contributions of PPG to overall hyperglycemia at baseline and week 26 of dulaglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3487079201
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among dulaglutide-treated Chinese patients, higher HbA1c was associated with lower postprandial glucose contributions at baseline and week 26.
In plain wordsIn Chinese patients receiving dulaglutide, higher HbA1c was linked to lower postprandial glucose contributions at baseline and during treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePostprandial glucose contribution by HbA1c
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Among patients receiving dulaglutide, higher HbA1c was associated with higher relative contributions of FG and lower relative contributions of PPG to overall hyperglycemia at baseline and week 26 of dulaglutide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This post-hoc analysis of the phase 3 AWARD-CHN2 trial included data from 560 Chinese patients with uncontrolled T2D who received once-weekly dulaglutide (1.5 or 0.75 mg) or once-daily glargine for 26 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3487079202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.